Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours

European Journal of Cancer

Volumn 28, Issue 11, 1992, Pages 1885-1889

  Scambia, Giovanni ^a   Ranelletti, Franco O ^a   Benedetti Panici, Pierluigi ^a   Piantelli, Mauro ^a   De Vincenzo, Rosa ^a   Bonanno, Guiseppina ^a   Ferrandina, Gabriella ^a   Isola, Giulio ^b   Mancuso, Salvatore ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Department of Pathology Catholic University ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ESTRADIOL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTICLE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

BINDING SITES; CISPLATIN; DRUG SYNERGISM; ESTROGENS; FEMALE; HUMAN; MITOSIS; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0026700109     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(92)90029-2     Document Type: Article

References (30)

1. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells
2. Type II oestrogen binding sites in acute lymphoid and non-lymphoid leukaemias. Growth inhibitory effect of oestrogen and flavonoids
3. Growth inhibitory effect of quercetin and presence of type II estrogen binding sites in human colon cancer cells lines and primary colorectal tumours
4. Synergistic antiproliferative activity of quercetin and cis-diamminedichloroplatinum on ovarian cancer cell growth
5. Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum (II)
6. Two binding sites for estradiol in rat uterine nuclei: relationship to uterotropic response
7. Type II estrogen-binding sites and 17 beta hydroxysteroid dehydrogenase activity in human peripheral blood mononuclear cells
8. Type II estrogen-binding sites in human colo-rectal carcinoma
9. Type II estrogen binding sites in a lymphoblastoid cell line and growth inhibitory effect of estrogen, antiestrogen and bioflavonoids
10. Quercetin inhibits the growth of a multidrug-resistant estrogen receptor negative MCF-7 human breast cancer cell line expressing type II estrogen binding sites
11. The effects of estrogen, progesterone and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro
12. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma
13. Primary bioassay of human stem cell
14. Criteria for analysing interaction between biologically active agents
15. Heterogeneity of estrogen binding sites in the cytosol of the rat uterus
16. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding
17. Revision of the standards for the assessment of hormone receptors in human breast cancer
18. 3H)-estradiol exchange
19. Growth patterns and hormonal sensitivity of primary tumour, abdominal metastasis and ascitic fluid from human epithelial ovarian carcinomas in the tumour colony-forming assay
20. Changes in calcium channel activity in membranes from CIS-diamine-dichloroplatinum (II)-resistant and sensitive L1210 cells
21. Ca-dependent binding of tamoxifen to calmodulin isolated from bovine brain
22. Opposite effect of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells
23. Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay
24. In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumour clonogenic assay
25. Cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment
26. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient
27. Differential uptake of cis-diamminedichloplatinum (II) by sensitive and resistant murine L1210 leukemia cells
28. Antitumour activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1, 1-diamminethylcyclohexane platinum (II) surfate, and of cis-diamminedichloplatinum (II) in an immunocytoma model in the LOU/M rat
29. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer
30. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data